Pfizer receives FDA OK for Zavzpret

The Food and Drug Administration has given Pfizer the green light for Zavzpret (zavegepant), the first and only calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.

“The FDA approval of Zavzpret marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications,” said Angela Hwang, chief commercial officer and president of the global biopharmaceuticals business at Pfizer. “Zavzpret underscores Pfizer’s commitment to delivering an additional treatment option to help people with migraine gain relief and get back to their daily lives. Pfizer will continue to build its migraine franchise to further support the billions of people worldwide impacted by this debilitating disease.”

[Read more: Pfizer, BioNTech COVID-19 vaccine gets emergency use authorization]

“When a migraine hits, it has a significant negative impact on a person’s daily life,” said Kathleen Mullin, associate medical director at New England Institute for Neurology & Headache. “Among my migraine patients, one of the most important attributes of an acute treatment option is how quickly it works. As a nasal spray with rapid drug absorption, Zavzpret offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting, so they can get back to normal function quickly.”

Zavzpret is expected to be available in pharmacies in July 2023.

[Read more: Upsher-Smith offers help to people with migraines during Migraine Month]